Metabolism of the Host and Microbes to Modulate ImmunocytesView this Special Issue
Research Article | Open Access
Rui Yu, Yunyun Mao, Kai Li, Yanfang Zhai, Yue Zhang, Shuling Liu, Yuemei Gao, Zhengshan Chen, Yanhong Liu, Ting Fang, Mengsu Zhao, Ruihua Li, Junjie Xu, Wei Chen, "Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection", Mediators of Inflammation, vol. 2021, Article ID 9979032, 9 pages, 2021. https://doi.org/10.1155/2021/9979032
Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection
Coronaviruses (CoVs) are enveloped and harbor an unusually large (30–32 kb) positive-strand linear RNA genome. Highly pathogenic coronaviruses cause severe acute respiratory syndrome (SARS) (SARS-CoV and SARS-CoV-2) and Middle East respiratory syndrome (MERS) (MERS-CoV) in humans. The coronavirus mouse hepatitis virus (MHV) infects mice and serves as an ideal model of viral pathogenesis, mainly because experiments can be conducted using animal-biosafety level-2 (A-BSL2) containment. Human thymosin beta-4 (Tβ4), a 43-residue peptide with an acetylated N-terminus, is widely expressed in human tissues. Tβ4 regulates actin polymerization and functions as an anti-inflammatory molecule and an antioxidant as well as a promoter of wound healing and angiogenesis. These activities led us to test whether Tβ4 serves to treat coronavirus infections of humans. To test this possibility, here, we established a BALB/c mouse model of coronavirus infection using mouse CoV MHV-A59 to evaluate the potential protective effect of recombinant human Tβ4 (rhTβ4). Such a system can be employed under A-BSL2 containment instead of A-BSL3 that is required to study coronaviruses infectious for humans. We found that rhTβ4 significantly increased the survival rate of mice infected with MHV-A59 through inhibiting virus replication, balancing the host’s immune response, alleviating pathological damage, and promoting repair of the liver. These results will serve as the basis for further application of rhTβ4 to the treatment of human CoV diseases such as COVID-19.
Coronaviruses (CoVs) that cause severe acute respiratory syndrome (SARS), such as SARS-CoV/SARS-CoV-2, and Middle East respiratory syndrome (MERS), such as MERS-CoV, are members of a large family of enveloped, single-stranded, positive-strand RNA viruses. Coronaviruses infect vertebrates and may cause acute respiratory distress syndrome (ARDS) with high morbidity and mortality rates, depending on species [1, 2].
The novel coronavirus pneumonia (COVID-19) outbreak and subsequent global pandemic caused by SARS-CoV-2 commenced around the end of 2019. When this manuscript was submitted for publication, there were more than 100 million cases and more than 2 million deaths worldwide. SARS-CoV-2, which is the seventh known coronavirus that infects humans, enters the respiratory system through the upper respiratory tract and eventually infects alveolar cells . The virus continuously proliferates, destroys the alveoli, and enters the capillaries. As blood circulates, the “battlefield” is further expanded, causing pathologies such as conjunctivitis, pneumonia, diarrhea, anosmia, abnormal liver function, renal failure, and heart damage that culminates in severe disease .
Mouse coronaviruses, also known as mouse hepatitis viruses (MHVs), are histologically classified as respiratory strains such as MHV-1, MHV-2, MHV-3, MHV-A59, and MHV-JHM as well as enterophilic strains such as MHV-y and MHV-R1. The respiratory strain MHV-A59 used here, as well as SARS-CoV and SARS-CoV-2, are β-coronaviruses. MHV-A59 can spread to numerous target organs after replicating in nasal epithelial cells. MHV is an excellent model for studying the pathogenesis, tropism, and virulence, as well as the host’s antiviral immune response. Further, MHV serves as a model for SARS-CoV infection. Moreover, MHV readily infects mice but not humans, and experiments can be conducted using animal-biosafety level-2 (A-BSL2) containment instead of A-BSL3 that is required for handling SARS-CoV and SARS-CoV-2 .
Thymosin beta-4 (Tβ4), an N-acetylated 43-amino acid residue peptide (molecular mass, 4960.5 Da; isoelectric point, 4.6) , is widely distributed among tissues of mammals and other vertebrates . Tβ4 possesses numerous biological activities such as inhibiting inflammation [8–13], preventing infection of wounds , inhibiting apoptosis [15–17] and scar formation [9, 15, 18], promoting cell migration and angiogenesis [19–21], accelerating collagen deposition, and upregulating the production of laminin-5 [22–27]. Nonclinical and clinical studies show the clinical importance of Tβ4 for treating dry eye, cardiac failure [19, 28], lung fibrosis [29, 30], septic shock , liver injury , and acute ischemic kidney injury [32, 33]. Tβ4 facilitates cardioprotection and regeneration of the ischemic heart by promoting the survival of cardiomyocytes through modulating the inflammatory environment and promoting neovascularization . Tβ4 possesses antioxidant, anti-inflammatory, and antifibrotic potential as demonstrated by studies of a mouse model of chronic liver injury . In a rat model of ischemic acute kidney injury, the beneficial therapeutic effects of Tβ4 are mediated through inhibition of extracellular matrix remodeling and apoptosis, as well as modulation of renal redox status and inflammation .
The multiple activities of Tβ4 may be useful for treating coronavirus infection. Specifically, Tβ4 may exert its biological activities at the molecular, cellular, and tissue levels to inhibit the “cytokine storm” caused by coronaviruses. Further, Tβ4 may play an important role in reconstituting the immune response, inhibiting inflammation, reducing lung injury, ameliorating pulmonary fibrosis, and reducing systemic sequelae of coronavirus pneumonia.
As proof of principle, here, we used recombinant human Tβ4 (rhTβ4) to evaluate the protective effect of rhTβ4 in a mouse model of MHV-A59 infection. Compared with chemically synthesized Tβ4, rhTβ4 has numerous advantages such as uniform quality, unlimited scale of production, relatively low production costs, and minimal adverse environmental effects. The results provide an experimental basis for applying rhTβ4 to the treatment of human CoV infection.
2. Materials and Methods
2.1. Virus, Cells, Mice, and rhTβ4
MHV-A59 was acquired from Guangdong Laboratory Animals Monitoring Institute of China. DBT cells were provided by the Chinese Experimental Animal Resources Research Institute for Food and Drug Control. Uninfected and MHV-A59-infected cells were passaged and preserved in our laboratory. Female SPF BALB/c mice (18–20 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. All animal experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee of Beijing Institution of Biotechnology (Identification code: IACUC-DWZX-2020-041; date of approval: 30 April 2020). Virus production and all animal experiments were performed in an A-BSL2 laboratory, and rhTβ4 was expressed and purified using our patented technology (Chinese invention patent No: ZL200910135972.0 and ZL201910498316.0) .
2.2. Reagents and Kits
The culture medium DMEM and fetal bovine serum (FBS) are products of Gibco. A Bio-Plex Pro Mouse Cytokine 23-plex Assay Kit (M60009RDPD) was purchased from Bio-Rad Laboratories, Inc. A Mouse C-Reactive Protein ELISA Kit (ab222511) was purchased from Abcam. An MHV-Ab ELISA Kit (DG30747M) was purchased from Beijing Winter Song Boye Biotechnology Co. Ltd, China. An RNeasy Plus Mini Kit (74136), a QuantiTect Reverse Transcription Kit (205311), and a QuantiTect Probe PCR Kit (204343) were purchased from QIAGEN. Paraformaldehyde (4%) was purchased from Beijing Solarbio Technology Co. Ltd, China. RNAstore reagent was purchased from TIANGEN Biotech (Beijing) Co. Ltd, China. The preparation of sections for histopathological analysis and hematoxylin-eosin (HE) staining of mouse organs was performed by Beijing Soonbio Technology Co., Ltd, China.
2.3. Virus Propagation and Titer Determination
DBT cells were cultured at 37°C in an atmosphere containing 5% CO2 in DMEM containing 5% FBS in culture flasks filled to 90% capacity. The virus growth medium was then replaced with DMEM containing 2% FBS, and MHV-A59 () was added. The cells were monitored each day. When >75% of the cells exhibited cytopathic effects, the culture flask was frozen at –80°C and thawed. The supernatant was collected and centrifuged for 5 min at 1000 × g to remove cells. The supernatants were frozen and stored at –80°C. The TCID50 of the virus was calculated using the method of Reed-Muench .
2.4. Infection of Mice and Administration of rhTβ4
SPF BALB/mice () were randomly divided into the groups as follows: sham, placebo, and rhTβ4. Each of the eight mice in the sham group was intraperitoneally injected with 0.1 mL of normal saline (NS) daily from days 0 to 10 (Figure 1). The eight mice in the placebo group were each intraperitoneally injected with TCID50 of MHV-A59 on day 0, and 0.1 mL NS was intraperitoneally injected into each mouse once daily from days 1 to 10. The mice in the rhTβ4 group were intraperitoneally injected with TCID50 of MHV-A59 per mouse on day 0, and 300 μg of rhTβ4 in 0.1 mL NS was intraperitoneally injected per mouse daily from days 1 to 10. The mice in each group were observed until day 14.
These experiments were then repeated with the same groups and dosing schedule, and the number of mice was increased to 12 in each group for next analysis.
The surviving mice were weighed on days 0, 2, 5, 8, and 14. Food consumption of each group was monitored by weighing the food on days 3, 6, 10, and 14. Blood was collected from the tail vein of surviving mice, and the serum was separated on days 1, 3, and 14. On days 3 and 14, 3 mice in each group were killed, and the liver, lung, and kidney tissues were collected. The tissues were stored in 4% paraformaldehyde or in RNAstore reagent. Two mice in the placebo group survived, and their data on day 14 were combined.
2.5. Analysis of Anti-MHV Antibodies
The tail vein blood of the surviving mice in each group was collected on day 14 into serum separator tubes. The blood was allowed to clot for 2 h at room temperature before centrifugation for 20 min at approximately 1000 × g. The freshly prepared serum was immediately assayed using the MHV-Ab ELISA Kit. A standard curve was generated using six concentrations of the standard, and the concentration of the anti-MHV antibodies was evaluated.
2.6. Quantitative Real-Time Polymerase Chain Reaction (qPCR) Analysis of Viral RNA in Mouse Tissues
The qPCR assays employed a TaqMan probe to quantify MHV-A59 RNA in liver, lung, and kidney tissues of mice 3 and 14 days postinfection. The sequences of the primers and TaqMan probe were designed according to the MHV-A59 sequence (GenBank No. FJ6742245) as follows: MHV-F: 5 –ggaacttctcgttgggcattatact–3; MHV-R: 5–tatgttgtgaaaatgataatcttgtggt–3; MHV-probe: FAM-acatgctacggctcgtgtaaccgaactgt-BHQ1. A 130-bp DNA fragment which contained the T7 promoter sequence and a specific sequence from MHV-A59, was cloned into the pCloneEZ-TOPO-NRS-Amp vector (Taihe Biotechnology, Beijing, China) as a positive control. The copy numbers of the plasmid containing the 130 bp insert were estimated to serve as standards.
Tissue RNAs prepared using a RNeasy Plus Mini Kit were reverse transcribed with a QuantiTect Reverse Transcription Kit and quantitated according to the protocol supplied with the QuantiTect Probe PCR Kit. TaqMan reaction mixtures (20 μL) contained 10 μL of 2× Master Mix, 400 nM MHV-F or MHV-R primer, 200 nM MHV probe, and 2 μL of cDNA template. After initial denaturation at 95°C for 10 min, 40 amplification cycles were performed, which included melting and annealing steps at 95°C, 15 s and 60°C and 60°s, respectively. Amplification, detection, and data analysis were performed using an ABI 7500 Real-Time PCR system (Applied Biosystems, USA).
2.7. Cytokine Assays
Cytokines in mouse sera were detected using a Bio-Plex Pro Mouse Cytokine 23-plex Assay Kit according to the protocol provided by the manufacturer. Data were acquired using a Bio-Plex 200 System (Bio-Rad, USA). The cytokines tested were as follows: IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 p40, IL-12 p70, IL-13, IL-17A, eotaxin, G-CSF, GM-CSF, IFN-γ, KC, MCP-1 (MCAF), MIP-1α, MIP-1β, RANTES, and TNF-α.
2.8. C-Reactive Protein (CRP) Assay
The CRP concentrations in mouse sera were measured using a Mouse C-Reactive Protein ELISA Kit according to the protocol provided by the manufacturer. The quantity of CRP was interpolated from a standard curve.
2.9. Hematoxylin-Eosin (HE) Staining
Liver, lung, and kidney tissues were harvested on days 3 and 14 postinfection and stored in 4% paraformaldehyde. Pathological injury and inflammation in the HE-stained samples were observed and recorded.
2.10. Statistical Analysis
Data represent the of each treatment group. The significance of the differences of survival rates between groups was analyzed using a log-rank (Mantel-Cox) test. A Student unpaired -test was used to determine the significance of the difference between two independent datasets, two-way ANOVA was used to determine the significance of the difference between two groups, and represents a significant difference.
3.1. Effects of rhTβ4 on Mice Infected with MHV-A59
Mice in the placebo group began to show typical signs of illness from day 2 postinfection, including difficulty walking, hunched posture, and erect and piled up hair. These mice began to die from day 4 postinfection, while mice in the rhTβ4 group began to die on day 6 postinfection. The survival rates of mice in the placebo and rhTβ4 groups were 12.5% and 75%, respectively () (Figure 2(a)).
Mice in the placebo and rhTβ4 groups lost appetite, and their body weights started decreasing on day 2 postinfection, compared with those of the mice in the sham group (Figure 2(b)). The weight loss of mice in the rhTβ4 group was lower compared with that of the placebo group () and gradually increased starting from day 8 postinfection. Food consumption of mice in the placebo and the rhTβ4 groups significantly decreased after challenge. The lowest food consumption occurred from days 3 to 6 postinfection and then gradually increased (Figure 2(c)).
3.2. Anti-MHV Antibody Concentrations
MHV specific antibodies were detected in the sera of survivors on day 14 postinfection. MHV-A59 challenge elicited titers of specific antibodies in the placebo and rhTβ4 groups. The anti-MHV antibody concentrations in group rhTβ4 were significantly lower compared with those of the placebo group () (Figure 3).
3.3. Viral RNA Copy Numbers in Tissues
The number of MHV-A59 RNA copies in the liver wasthe highest, followed by the lung and kidney. On day 3 postinfection, the viral RNA copies of liver tissues in the rhTβ4 group were significantly lower compared with those of the placebo group (), and there was no significant difference between viral RNA copy numbers in the tissues of these group on day 14 after challenge. Further, these values did not significantly differ between the rhTβ4 placebo groups (Figure 4).
3.4. Cytokine and CRP Levels
As shown in Table 1, on day 3 postinfection, the concentrations of 18 of 23 cytokines in the sera of both the placebo and rhTβ4 groups were significantly increased vs normal values (). The levels of the four cytokines were not significantly different. On day 14 postinfection, the levels of the 23 cytokines in the rhTβ4 group returned to normal, while the concentrations of 11 cytokines in the placebo group were significantly lower compared with normal values (). There was no significant change in the CRP concentration of each group during the experiment (Figure 5). These results indicate that MHV-A59 significantly inhibited the immune response of mice in the late stage of virus infection and during convalescence. However, rhTβ4 effectively balanced the levels of proinflammatory and anti-inflammatory cytokines to maintain physiological immune homeostasis.
3.5. Protection from Tissue Injury
There was no significant injury to the lungs or kidneys of the placebo and rhTβ4 groups. In contrast, MHV-A59 caused severe liver injury. For example, day 3 postinfection of mice in the placebo group caused hepatocyte necrosis, watery degeneration, inflammatory cell infiltration (including granulocytes and mononuclear cells), and bleeding in some necrotic areas of the liver. The rhTβ4 group exhibited hepatocyte necrosis, watery degeneration, and minimal infiltration by inflammatory cells of the liver. Compared with mice in the placebo group, the rate and degrees of inflammatory cell infiltration of mice in the rhTβ4 group decreased by day 14 postinfection, and hepatocyte necrosis was repaired in mice in the placebo group; although, there was watery degeneration and inflammatory cell infiltration (the number of Kupffer cells increased) and minimal hepatocyte regeneration. The rhTβ4 group exhibited hepatocyte regeneration (binucleate and macronuclear regenerated hepatocytes). Compared with the placebo group, the livers of the rhTβ4 group underwent injury repair, and hepatocyte proliferation was detected (Figure 6).
Here, we show that MHV can be used as a model to screen for drugs that inhibit CoV infection under A-BLS2 containment. In contrast, studies of CoVs that are pathogenic for humans such as CoV-2 require A-BSL3 containment and the use of transgenic mice that express the CoV-2 receptor, human angiotensin-converting enzyme 2 .
The anti-inflammatory activities of Tβ4 suggested to us that it may serve to treat coronavirus infections of humans. Further, Han et al. found an association between reductions in serum levels Tβ4 and the severity of liver failure caused by chronic HBV infection , and Shahabuddin et al. found that chronic infection with HIV-1 reduces the level of Tβ4 in infected cells .
Here, we show that rhTβ4 increased the survival rate of mice infected with MHV-A59, significantly reduced viral titers in the liver during the early stage of infection, protected the liver from severe injury, and promoted hepatocyte regeneration and tissue repair. There was no significant difference in the numbers of virus RNA copies of tissues between the placebo and rhTβ4 groups during the later stage of infection. However, the anti-MHV-specific antibody titers of the rhTβ4 group were significantly lower compared with those of the placebo group 14 days postinfection. This may be explained by the discordance between viral RNA copy numbers and the number of infectious viruses.
T helper cells (Th) play an important role in regulating the immune system. Th1 cells inhibit virus infection leading to inflammation or delayed type hypersensitivity through the secretion of cytokines such as IL-1, IFN-γ, and TNF-β. Th2 cells produce numerous cytokines (e.g., IL-4, IL-5, IL-6, IL-10, and IL-13) that induce B cells to mount a humoral immune response . Th cells produce proinflammatory (e.g., TNF - α, IL-2, IL-6, IL-8, IL-12, IL-17, IL-23, IFN γ, and MIF) and anti-inflammatory cytokines (e.g., IL-4, IL-13, IL-10, TGF - β, and IL-1R α). Under normal physiological conditions, Th1 and Th2 cells maintain a balanced state of mutual inhibition and proliferation. The dynamic balance of proinflammatory and anti-inflammatory cytokines determines the development and outcome of inflammation. An imbalance in cytokine activities leads to pathology. Three days after MHV-A59 infection, the concentrations of anti-inflammatory and proinflammatory cytokines significantly increased, and all the physical characteristics of the mice, histopathology, cytokine assays suggested that the mice infected with MHV-A59 were in the “cytokine storm” state. The mice in the placebo group began to recover 14 days postinfection, as indicated by increased body weight and food consumption. However, the levels of 11 cytokines in the placebo group were significantly lower compared with their normal values, indicating that the virus significantly inhibited the activities of Th1 and Th2 cells to suppress the antiviral immune response. However, the level of each of the 23 cytokines produced by rhTβ4-treated mice returned to normal 14 days after challenge. These results show that rhTβ4 effectively balanced the activities of Th1 and Th2 cells as well as the concentrations of proinflammatory and anti-inflammatory cytokines to restore normal immune homeostasis.
Only two survived mice data were detected in the placebo group at 14 d.p.i., which is a small shortcoming of this study. Although we had tried different challenge doses of MHV-A59, no more mice in the placebo group could survive under the condition that the survival rate was statistically different, unless the sample size was particularly large. We will further increase the number of mice to acquire more data in the next study.
MHV-A59 can be used as a model virus to study CoVs under conditions of A-BSL2 containment. As proof of principle, we show here that although rhTβ4 was not virucidal, it protected mice from virus challenge by balancing the immune response, promoting the regeneration of damaged cells, and repairing tissue damage, leading to rapid mitigation of the pathological consequences of CoV infection.
The data used to support the findings of this study are available from the corresponding author upon request.
Highlights. This was the first report of recombinant human thymosin beta-4 (rhTβ4) in the treatment of mouse coronavirus infection, which showed that rhTβ4 significantly increased the survival rate of mice infected with MHV-A59 through inhibiting virus replication, balancing the host’s immune response, alleviating pathological damage, and promoting repair of the liver. These results will serve as the basis for further application of rhTβ4 to the treatment of human CoV diseases such as COVID-19.
Conflicts of Interest
The authors declare that they have no conflicts of interest with the contents of this article.
Rui Yu, Junjie Xu, and Wei Chen concepted and designed the study. Rui Yu, Yunyun Mao, Kai Li, Yanfang Zhai, Yue Zhang, Shuling Liu, Yuemei Gao, Yanhong Liu, Ting Fang, and Mengsu Zhao performed the experiments. Zhengshan Chen and Ruihua Li analyzed the data. Junjie Xu drafted the article and revised it critically for the important intellectual content. Wei Chen finally approved of the version to be submitted.
- S. R. Weiss and S. Navas-Martin, “Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus,” Microbiology and Molecular Biology Reviews, vol. 69, no. 4, pp. 635–664, 2005.
- D. Schoeman and B. C. Fielding, “Coronavirus envelope protein: current knowledge,” Virology Journal, vol. 16, no. 1, p. 69, 2019.
- Y. A. Malik, “Properties of coronavirus and SARS-CoV-2,” The Malaysian Journal of Pathology, vol. 42, no. 1, pp. 3–11, 2020.
- X. Yang, Y. Yu, J. Xu et al., “Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study,” The Lancet Respiratory Medicine, vol. 8, no. 5, pp. 475–481, 2020.
- R. W. Körner, M. Majjouti, M. A. A. Alcazar, and E. Mahabir, “Of mice and men: the coronavirus MHV and mouse models as a translational approach to understand SARS-CoV-2,” Viruses, vol. 12, no. 8, p. 880, 2020.
- E. Hannappel, “Thymosin β4 and its posttranslational modifications,” Annals of the New York Academy of Sciences, vol. 1194, no. 1, pp. 27–35, 2010.
- S. K. Hu, T. L. Low, and A. L. Goldstein, “Modulation of terminal deoxynucleotidyl transferase activity by thymosin,” Molecular and Cellular Biochemistry, vol. 41, pp. 49–58, 1981.
- M. Badamchian, M. O. Fagarasan, R. L. Danner, A. F. Suffredini, H. Damavandy, and A. L. Goldstein, “Thymosin β4 reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock,” International Immunopharmacology, vol. 3, no. 8, pp. 1225–1233, 2003.
- M. A. Cavasin, “Therapeutic potential of thymosin-beta4 and its derivative N-acetyl-seryl-aspartyl-lysyl-proline (ac-SDKP) in cardiac healing after infarction,” American Journal of Cardiovascular Drugs, vol. 6, no. 5, pp. 305–311, 2006.
- G. Sosne, E. A. Szliter, R. Barrett, K. A. Kernacki, H. Kleinman, and L. D. Hazlett, “Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury,” Experimental Eye Research, vol. 74, no. 2, pp. 293–299, 2002.
- G. Sosne, P. Qiu, P. L. Christopherson, and M. K. Wheater, “Thymosin beta 4 suppression of corneal NFκB: A potential anti-inflammatory pathway,” Experimental Eye Research, vol. 84, no. 4, pp. 663–669, 2007.
- G. Sosne, P. L. Christopherson, R. P. Barrett, and R. Fridman, “Thymosin-β4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury,” Investigative Ophthalmology & Visual Science, vol. 46, no. 7, pp. 2388–2395, 2005.
- J. D. Young, A. J. Lawrence, A. G. MacLean et al., “Thymosin β 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids,” Nature Medicine, vol. 5, no. 12, pp. 1424–1427, 1999.
- L. C. Huang, D. Jean, R. J. Proske, R. Y. Reins, and A. M. McDermott, “Ocular surface expression and in vitro activity of antimicrobial peptides,” Current Eye Research, vol. 32, no. 7-8, pp. 595–609, 2007.
- I. Bock-Marquette, A. Saxena, M. D. White, J. Michael DiMaio, and D. Srivastava, “Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair,” Nature, vol. 432, no. 7016, pp. 466–472, 2004.
- J. H. Ho, K. C. Tseng, W. H. Ma, K. H. Chen, O. K. S. Lee, and Y. Su, “Thymosin beta-4 upregulates anti-oxidative enzymes and protects human cornea epithelial cells against oxidative damage,” The British Journal of Ophthalmology, vol. 92, no. 7, pp. 992–997, 2008.
- J. H. Ho, C. H. Chuang, C. Y. Ho, Y. R. V. Shih, O. K. S. Lee, and Y. Su, “Internalization is essential for the antiapoptotic effects of exogenous thymosin β-4 on human corneal epithelial cells,” Investigative Ophthalmology & Visual Science, vol. 48, no. 1, pp. 27–33, 2007.
- H. P. Ehrlich and S. W. Hazard III, “Thymosin β4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts,” Annals of the New York Academy of Sciences, vol. 1194, no. 1, pp. 118–124, 2010.
- N. Smart, C. A. Risebro, A. A. D. Melville et al., “Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization,” Nature, vol. 445, no. 7124, pp. 177–182, 2007.
- K. M. Malinda, A. L. Goldstein, and H. K. Kueinman, “Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells,” The FASEB Journal, vol. 11, no. 6, pp. 474–481, 1997.
- D. S. Grant, J. L. Kinsella, M. C. Kibbey et al., “Matrigel induces thymosin beta 4 gene in differentiating endothelial cells,” Journal of Cell Science, vol. 108, Part 12, pp. 3685–3694, 1995.
- G. Sosne, A. Siddiqi, and M. Kurpakus-Wheater, “Thymosin-β4 inhibits corneal epithelial cell apoptosis after ethanol exposure in vitro,” Investigative Ophthalmology & Visual Science, vol. 45, no. 4, pp. 1095–1100, 2004.
- P. Qiu, M. Kurpakus-Wheater, and G. Sosne, “Matrix metalloproteinase activity is necessary for thymosin beta 4 promotion of epithelial cell migration,” Journal of Cellular Physiology, vol. 212, no. 1, pp. 165–173, 2007.
- P. Roy, Z. Rajfur, D. Jones, G. Marriott, L. Loew, and K. Jacobson, “Local photorelease of caged thymosin β4 in locomoting keratocytes causes cell turning,” The Journal of Cell Biology, vol. 153, no. 5, pp. 1035–1048, 2001.
- G. Sosne, S. Hafeez, A. L. Greenberry, and M. Kurpakus-Wheater, “Thymosin beta4 promotes human conjunctival epithelial cell migration,” Current Eye Research, vol. 24, no. 4, pp. 268–273, 2002.
- G. Sosne, L. Xu, L. Prach et al., “Thymosin beta 4 stimulates laminin-5 production independent of TGF-beta,” Experimental Cell Research, vol. 293, no. 1, pp. 175–183, 2004.
- G. Sosne, P. Qiu, A. L. Goldstein, and M. Wheater, “Biological activities of thymosin beta4 defined by active sites in short peptide sequences,” The FASEB Journal, vol. 24, no. 7, pp. 2144–2151, 2010.
- S. Bollini, P. R. Riley, and N. Smart, “Thymosin β4: multiple functions in protection, repair and regeneration of the mammalian heart,” Expert Opinion on Biological Therapy, vol. 15, Supplement 1, pp. 163–174, 2015.
- E. Conte, T. Genovese, E. Gili et al., “Thymosin β4 protects C57BL/6 mice from bleomycin-induced damage in the lung,” European Journal of Clinical Investigation, vol. 43, no. 3, pp. 309–315, 2013.
- E. Conte, T. Genovese, E. Gili et al., “Protective effects of thymosin β4 in a mouse model of lung fibrosis,” Annals of the New York Academy of Sciences, vol. 1269, no. 1, pp. 69–73, 2012.
- R. Shah, K. Reyes-Gordillo, Y. Cheng, R. Varatharajalu, J. Ibrahim, and M. R. Lakshman, “Thymosin β4 prevents oxidative stress, inflammation, and fibrosis in ethanol- and LPS-induced liver injury in mice,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 9630175, 12 pages, 2018.
- E. Vasilopoulou, P. J. D. Winyard, P. R. Riley, and D. A. Long, “The role of thymosin-β4 in kidney disease,” Expert Opinion on Biological Therapy, vol. 15, Supplement 1, pp. 187–190, 2015.
- U. Aksu, O. M. Yaman, I. Guner et al., “The protective effects of Thymosin-β-4 in a rat model of ischemic acute kidney injury,” Journal of Investigative Surgery, vol. 8, pp. 1–9, 2019.
- R. Yu, S. Cao, Y. Liu et al., “Highly effective biosynthesis ofN-acetylated human thymosin β4 (Tβ4) inEscherichia coli,” Artificial Cells, Nanomedicine, and Biotechnology, vol. 46, Supplement 3, pp. S95–S104, 2018.
- D. L. Krah, “A simplified multiwell plate assay for the measurement of hepatitis a virus infectivity,” Biologicals, vol. 19, no. 3, pp. 223–227, 1991.
- L. Bao, W. Deng, B. Huang et al., “The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice,” Nature, vol. 583, no. 7818, pp. 830–833, 2020.
- T. Han, Y. Liu, H. Liu et al., “Serum thymosin beta4 levels in patients with hepatitis B virus-related liver failure,” World Journal of Gastroenterology, vol. 16, no. 5, pp. 625–630, 2010.
- M. Shahabuddin, G. McKinley, M. J. Potash, and D. J. Volsky, “Modulation of cellular gene expression of HIV type 1 infection as determined by subtractive hybridization cloning: downregulation of thymosin beta 4 in vitro and in vivo,” AIDS Research and Human Retroviruses, vol. 10, no. 11, pp. 1525–1529, 1994.
- P. Kidd, “Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease,” Alternative Medicine Review, vol. 8, no. 3, pp. 223–246, 2003.
Copyright © 2021 Rui Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.